Study Stopped
due to COVID-19 pandemia
Myocardial Injury and Severe Pneumococcal Pneumonia
NEUMOCAR
Myocardial Injury in Severe Pneumococcal Pneumonia as a Cause of Mortality From Acute Cardiovascular Events
1 other identifier
observational
23
1 country
1
Brief Summary
Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery (pneumolysin) or different biomarkers (histones, NETs(neutrophil extracellular traps), IL (Interleukin)-1b,h-Fabp (heart-Fatty acid bindding protein) ).The CVE frequency and its impact on outcome in patients without prior heart disease (CP) has not been studied. Objectives:1) To determine the incidence of myocardian injury (MI) and CVE in patients with CAP without CP evaluated by non-invasive techniques (Echocardiograph and MRI) and biomarkers levels (Tn-I (Troponin I), h-Fabp, NT-proBNP (N-terminal pro-brain natriuretic peptide) histones, NETs, IL 1b); 2) To assess if DMA and CVE are related to the etiology and their impact on outcome , 3) To investigate the presence of myocardial scarring by MRI and its relationship with etiology and MI, and 4) To identify prognostic factors of DMA and CVE to determine level of risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 10, 2017
CompletedFirst Posted
Study publicly available on registry
February 20, 2017
CompletedStudy Start
First participant enrolled
March 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedJuly 1, 2021
June 1, 2021
1.2 years
February 10, 2017
June 29, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Myocardian injury (scarring) in patients with CAP without cardiac disease (CP)history at 6 months of ICU admission
MRI with late gadolinium increase and t1 mapping techniques for to detect myocardial scarring
at 6 months
Heart dysfunction in patients with CAP without cardiac disease (CP)history in the first week of ICU admission
Echocardiography with standard and strain techniques for to detect the presence of decrease in ejection fraction of both vetricules
at day 7 of ICU admission)
Secondary Outcomes (3)
Temporal profile of the Troponin I as a cardiac injury biomarker in patients with CAP without cardiac disease (CP)history in the first week of ICU admission
once per day ( days 1 to 7 of ICU admission)
Temporal profile of the N-terminal pro-brain natriuretic peptide(NT-proBNP) as a cardiac injury biomarker in patients with CAP without cardiac disease (CP)history in the first week of ICU admission
once per day (days 1 to 7 of ICU admission)
Temporal profile of the heart- fatty acid binding protein (h-Fabp) as a cardiac injury biomarker in patients with CAP without cardiac disease (CP)history in the first week of ICU admission
once per day (days 1 to 7 of ICU admission)
Study Arms (2)
pneumococcal pneumonia
Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
non-pneumococcal pneumonia
Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
Interventions
Standard protocols
MRI with late gadolinium increase and T1 mapping
Eligibility Criteria
Critically ill patients admitted to the intensive care unit due to severe community-acquired pneumonia
You may qualify if:
- \- Patients admitted to the ICU due to community-acquired pneumonia according to IDSA/ATS criteria
- \- No history of heart diasese
- \- Informed consent signed
You may not qualify if:
- \- Hospital or ventilator-associated pneumonia
- \- Health care-associated pneumonia
- \- Viral pneumonia
- \- Bacterial/viral coinfection pneumonia
- \- History of heart disease
- \- Chronic administration of statins
- \- Chronic administration of steorids (Prednisolone more 20 mg/day or equivalent)
- \- No signed informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Critical Care Department - Hospital Universitario de Tarragona Joan XXIII
Tarragona, 43007, Spain
Related Publications (4)
Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet. 2013 Feb 9;381(9865):496-505. doi: 10.1016/S0140-6736(12)61266-5. Epub 2013 Jan 16.
PMID: 23332146BACKGROUNDAlhamdi Y, Neill DR, Abrams ST, Malak HA, Yahya R, Barrett-Jolley R, Wang G, Kadioglu A, Toh CH. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015 May 14;11(5):e1004836. doi: 10.1371/journal.ppat.1004836. eCollection 2015 May.
PMID: 25973949BACKGROUNDBrown AO, Mann B, Gao G, Hankins JS, Humann J, Giardina J, Faverio P, Restrepo MI, Halade GV, Mortensen EM, Lindsey ML, Hanes M, Happel KI, Nelson S, Bagby GJ, Lorent JA, Cardinal P, Granados R, Esteban A, LeSaux CJ, Tuomanen EI, Orihuela CJ. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014 Sep 18;10(9):e1004383. doi: 10.1371/journal.ppat.1004383. eCollection 2014 Sep.
PMID: 25232870BACKGROUNDLee YJ, Lee H, Park JS, Kim SJ, Cho YJ, Yoon HI, Lee JH, Lee CT, Park JS. Cardiac troponin I as a prognostic factor in critically ill pneumonia patients in the absence of acute coronary syndrome. J Crit Care. 2015 Apr;30(2):390-4. doi: 10.1016/j.jcrc.2014.12.001. Epub 2014 Dec 4.
PMID: 25534985BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alejandro H Rodriguez Oviedo
Hospital Universitari de Tarragona Joan XXIII
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD,PhD
Study Record Dates
First Submitted
February 10, 2017
First Posted
February 20, 2017
Study Start
March 1, 2018
Primary Completion
May 31, 2019
Study Completion
December 31, 2019
Last Updated
July 1, 2021
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share